首页 > 最新文献

Australasian Journal of Dermatology最新文献

英文 中文
Psychological Wellbeing After a Diagnosis of Melanoma In Situ: A Qualitative Interview Study. 原位黑色素瘤诊断后的心理健康:一项定性访谈研究。
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-02-11 DOI: 10.1111/ajd.70041
Lejie Zheng, Saidee Beigi, Solange Green, Caitlin Horsham, Monika Janda, Richard Johns, Peter Soyer, Soraia De Camargo Catapan

Background: Melanoma rates are on the rise in Australia, with melanoma in situ (MIS) increasing at an even faster rate, highlighting a growing trend reflecting improved detection of early-stage melanoma. The aim of this study is to explore the psychological impact associated with receiving a MIS diagnosis.

Methods: Individuals diagnosed with MIS within 1 year participated in semi-structured interviews. Data were analysed using reflexive thematic analysis and reported following Holland's research model.

Results: Nine main themes were identified, reflecting a wide range of immediate responses and evolving concerns over time, with differences evident between younger and older participants. Participants reported the use of coping strategies, support systems, and that they changed their sun safety behaviours post-diagnosis.

Conclusions: Findings demonstrated varied psychological responses to MIS diagnosis by life course and coping strategies, highlighting the need for future research to address psychological needs through tailored and context-specific interventions.

背景:澳大利亚的黑色素瘤发病率正在上升,其中原位黑色素瘤(MIS)的增长速度更快,这一增长趋势反映了早期黑色素瘤检测的提高。本研究的目的是探讨与接受MIS诊断相关的心理影响。方法:对1年内诊断为MIS的个体进行半结构化访谈。数据分析使用反身性主题分析,并按照荷兰的研究模式进行报告。结果:确定了九个主要主题,反映了广泛的即时反应和随着时间的推移而演变的关注,在年轻和年长的参与者之间存在明显的差异。参与者报告了应对策略、支持系统的使用,并在诊断后改变了他们的阳光安全行为。结论:研究结果表明,不同的生命历程和应对策略对MIS诊断的心理反应不同,强调了未来研究需要通过量身定制和特定情境的干预措施来解决心理需求。
{"title":"Psychological Wellbeing After a Diagnosis of Melanoma In Situ: A Qualitative Interview Study.","authors":"Lejie Zheng, Saidee Beigi, Solange Green, Caitlin Horsham, Monika Janda, Richard Johns, Peter Soyer, Soraia De Camargo Catapan","doi":"10.1111/ajd.70041","DOIUrl":"https://doi.org/10.1111/ajd.70041","url":null,"abstract":"<p><strong>Background: </strong>Melanoma rates are on the rise in Australia, with melanoma in situ (MIS) increasing at an even faster rate, highlighting a growing trend reflecting improved detection of early-stage melanoma. The aim of this study is to explore the psychological impact associated with receiving a MIS diagnosis.</p><p><strong>Methods: </strong>Individuals diagnosed with MIS within 1 year participated in semi-structured interviews. Data were analysed using reflexive thematic analysis and reported following Holland's research model.</p><p><strong>Results: </strong>Nine main themes were identified, reflecting a wide range of immediate responses and evolving concerns over time, with differences evident between younger and older participants. Participants reported the use of coping strategies, support systems, and that they changed their sun safety behaviours post-diagnosis.</p><p><strong>Conclusions: </strong>Findings demonstrated varied psychological responses to MIS diagnosis by life course and coping strategies, highlighting the need for future research to address psychological needs through tailored and context-specific interventions.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146155750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical Diltiazem in the Management of Cutaneous Leiomyoma-Associated Pain: Evaluation With a Cold-Provocation Test. 局部地尔硫卓治疗皮肤平滑肌瘤相关疼痛:用冷激发试验评价。
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-02-09 DOI: 10.1111/ajd.70060
Samet Öner, Ceylan Avcı, Arzu Avcı

Cutaneous leiomyomas can cause severe pain that may be spontaneous or stimulus-evoked, and is commonly exacerbated by cold exposure, mechanical pressure/touch, or stress. We report a patient with genetically confirmed hereditary leiomyomatosis and renal cell cancer (HLRCC) in whom topical diltiazem 2% was associated with reduced pain, assessed using a controlled cold-provocation test and validated pain scores. This brief report suggests that topical diltiazem may be a useful symptomatic option and supports further evaluation.

皮肤平滑肌瘤可引起剧烈疼痛,这种疼痛可能是自发的,也可能是刺激引起的,通常因冷暴露、机械压力/触摸或应激而加重。我们报告了一位遗传确诊的遗传性平滑肌瘤病和肾细胞癌(HLRCC)患者,使用对照冷激发试验和验证的疼痛评分评估,2%的局部地尔硫卓与疼痛减轻有关。这份简短的报告表明局部地尔硫卓可能是一种有用的对症治疗选择,并支持进一步的评估。
{"title":"Topical Diltiazem in the Management of Cutaneous Leiomyoma-Associated Pain: Evaluation With a Cold-Provocation Test.","authors":"Samet Öner, Ceylan Avcı, Arzu Avcı","doi":"10.1111/ajd.70060","DOIUrl":"https://doi.org/10.1111/ajd.70060","url":null,"abstract":"<p><p>Cutaneous leiomyomas can cause severe pain that may be spontaneous or stimulus-evoked, and is commonly exacerbated by cold exposure, mechanical pressure/touch, or stress. We report a patient with genetically confirmed hereditary leiomyomatosis and renal cell cancer (HLRCC) in whom topical diltiazem 2% was associated with reduced pain, assessed using a controlled cold-provocation test and validated pain scores. This brief report suggests that topical diltiazem may be a useful symptomatic option and supports further evaluation.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Costs Associated With Inpatient Management of Atopic Dermatitis in Paediatric Patients: An Australian Perspective. 与儿科患者特应性皮炎住院管理相关的费用:澳大利亚的观点。
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-02-05 DOI: 10.1111/ajd.70059
Zoe Lee, Leigh Mackey, Rachel Manifold
{"title":"Costs Associated With Inpatient Management of Atopic Dermatitis in Paediatric Patients: An Australian Perspective.","authors":"Zoe Lee, Leigh Mackey, Rachel Manifold","doi":"10.1111/ajd.70059","DOIUrl":"https://doi.org/10.1111/ajd.70059","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis. 阿达木单抗在澳大利亚银屑病患者中的实际疗效和药物生存期。
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-02-02 DOI: 10.1111/ajd.70024
N Punchihewa, J K Nguyen, J M Armstrong, S Vogrin, C Dolianitis, C Baker, G Marshman, J Frew, J Wu, P Lowe, P Foley

Background: Although adalimumab has shown strong efficacy and safety in clinical trials, real-world evidence in Australian patients with moderate-to-severe chronic plaque psoriasis is limited. This study assessed adalimumab efficacy and drug survival in routine clinical practice, comparing outcomes with the Phase 3 REVEAL trial and its open-label extension.

Methods: Data were extracted from the Australasian Psoriasis Registry for adults meeting Pharmaceutical Benefits Scheme criteria to be prescribed adalimumab for chronic plaque psoriasis. Baseline demographics, Psoriasis Area and Severity Index (PASI) scores and treatment history between June 2006 and March 2022 were analysed. Drug survival was evaluated using Kaplan-Meier and Cox regression.

Results: A total of 306 patients were included; 59.8% had prior biologic exposure compared to 12.8% in REVEAL. The mean baseline PASI was 24.1 and at 3 months, 63.5% achieved PASI75 while 33.6% achieved PASI90. PASI90 responses remained stable through 3 years and exceeded REVEAL extension rates beyond 18 months. Median drug survival was 27.9 months; survival was 97.7%, 78.6%, 63.7% and 51.0% at 3, 9, 15 and 27 months, respectively. Male sex and achieving PASI ≤ 2 predicted longer drug survival.

Conclusions: In Australian real-world practice, adalimumab demonstrated sustained effectiveness and drug survival in patients with chronic plaque psoriasis comparable to RCTs, despite higher baseline disease severity and greater prior biologic exposure.

背景:尽管阿达木单抗在临床试验中显示出强大的疗效和安全性,但在澳大利亚中重度慢性斑块性银屑病患者中的实际证据有限。该研究评估了阿达木单抗在常规临床实践中的疗效和药物生存期,并将结果与3期REVEAL试验及其开放标签扩展进行了比较。方法:从澳大利亚银屑病登记处提取符合药物福利计划标准的成人处方阿达木单抗治疗慢性斑块性银屑病的数据。分析了2006年6月至2022年3月期间的基线人口统计学、银屑病面积和严重程度指数(PASI)评分和治疗史。采用Kaplan-Meier和Cox回归评估药物生存期。结果:共纳入306例患者;59.8%的人之前有过生物暴露,而REVEAL的这一比例为12.8%。平均基线PASI为24.1,3个月时,63.5%达到PASI75, 33.6%达到PASI90。PASI90反应在3年内保持稳定,超过18个月的REVEAL延长率。中位药物生存期为27.9个月;3、9、15、27个月生存率分别为97.7%、78.6%、63.7%、51.0%。男性和达到PASI≤2预示着更长的药物生存期。结论:在澳大利亚的实际实践中,阿达木单抗在慢性斑块型银屑病患者中显示出与随机对照试验相当的持续有效性和药物生存期,尽管基线疾病严重程度更高,既往生物暴露程度更高。
{"title":"Real-World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis.","authors":"N Punchihewa, J K Nguyen, J M Armstrong, S Vogrin, C Dolianitis, C Baker, G Marshman, J Frew, J Wu, P Lowe, P Foley","doi":"10.1111/ajd.70024","DOIUrl":"https://doi.org/10.1111/ajd.70024","url":null,"abstract":"<p><strong>Background: </strong>Although adalimumab has shown strong efficacy and safety in clinical trials, real-world evidence in Australian patients with moderate-to-severe chronic plaque psoriasis is limited. This study assessed adalimumab efficacy and drug survival in routine clinical practice, comparing outcomes with the Phase 3 REVEAL trial and its open-label extension.</p><p><strong>Methods: </strong>Data were extracted from the Australasian Psoriasis Registry for adults meeting Pharmaceutical Benefits Scheme criteria to be prescribed adalimumab for chronic plaque psoriasis. Baseline demographics, Psoriasis Area and Severity Index (PASI) scores and treatment history between June 2006 and March 2022 were analysed. Drug survival was evaluated using Kaplan-Meier and Cox regression.</p><p><strong>Results: </strong>A total of 306 patients were included; 59.8% had prior biologic exposure compared to 12.8% in REVEAL. The mean baseline PASI was 24.1 and at 3 months, 63.5% achieved PASI75 while 33.6% achieved PASI90. PASI90 responses remained stable through 3 years and exceeded REVEAL extension rates beyond 18 months. Median drug survival was 27.9 months; survival was 97.7%, 78.6%, 63.7% and 51.0% at 3, 9, 15 and 27 months, respectively. Male sex and achieving PASI ≤ 2 predicted longer drug survival.</p><p><strong>Conclusions: </strong>In Australian real-world practice, adalimumab demonstrated sustained effectiveness and drug survival in patients with chronic plaque psoriasis comparable to RCTs, despite higher baseline disease severity and greater prior biologic exposure.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoimmune Disease Prevalence in Females With Vulval Lichen Sclerosus and Screening Patterns in a Multidisciplinary Vulval Unit. 外阴硬化地衣女性自身免疫性疾病患病率及多学科外阴筛查模式
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-02-02 DOI: 10.1111/ajd.70056
Monica Narula, Emma Veysey

Background/objectives: Vulval lichen sclerosus (LS) is a chronic inflammatory dermatosis with recognised associations with autoimmune disease, including thyroid disease, vitiligo, and psoriasis. Current expert consensus guidelines recommend investigating for autoimmune disease when clinically indicated by symptoms or signs. More recently, focused screening for thyroid disease and pernicious anaemia in women with LS has been proposed. This study aimed to assess the prevalence of autoimmune disease in a tertiary multidisciplinary vulval clinic and to determine whether findings from this cohort provide support for these proposed screening recommendations.

Methods: A retrospective review of electronic medical records was conducted for patients attending a tertiary women's hospital vulval dermatology service between August 2020 and June 2025 with a diagnosis of LS. Data extracted included autoimmune history, serological testing for autoimmune disease (including thyroid function and pernicious anaemia), and family history. Descriptive statistics were used for analysis.

Results: Eight hundred fifty-one patients met inclusion criteria. Autoimmune disease was recorded in 31.7%, with autoimmune thyroid disease (12.5%), lichen planus (8.23%), and psoriasis (5.05%) being most common. Inflammatory arthritis was present in 4.8% and autoimmune dermatological conditions in 18.4%. Serological screening was performed infrequently; thyroid stimulating hormone was performed in 18.4% of patients without known thyroid disease and 6.5% of these were abnormal. Vitamin B12 screening was performed in 8.9% and 10.5% were abnormal. Pernicious anaemia antibodies were performed in 0.35% and all were negative.

Conclusions: This single-centre cohort study demonstrated a high prevalence of autoimmune disease in women with LS, particularly thyroid disease, providing support for consideration of thyroid stimulating hormone screening. Serological testing for autoimmune disease was infrequently documented in this cohort, and the limited data on pernicious anaemia were insufficient to evaluate the proposed recommendation. The findings also highlight a high burden of autoimmune arthritis and other dermatological conditions, suggesting a role for clinical assessment in these domains. Prospective multicentre studies are required to inform and refine screening recommendations.

背景/目的:外阴硬化苔藓(LS)是一种慢性炎症性皮肤病,与自身免疫性疾病相关,包括甲状腺疾病、白癜风和牛皮癣。目前的专家共识指南建议在临床有症状或体征时调查自身免疫性疾病。最近,针对LS患者的甲状腺疾病和恶性贫血进行了重点筛查。本研究旨在评估自身免疫性疾病在三级多学科外阴诊所的患病率,并确定该队列的研究结果是否支持这些拟议的筛查建议。方法:回顾性分析2020年8月至2025年6月在某三级妇产医院外阴皮肤科就诊的LS患者的电子病历。提取的数据包括自身免疫性病史、自身免疫性疾病(包括甲状腺功能和恶性贫血)的血清学检测和家族史。采用描述性统计进行分析。结果:851例患者符合纳入标准。自身免疫性疾病占31.7%,其中甲状腺自身免疫性疾病(12.5%)、扁平苔藓(8.23%)和牛皮癣(5.05%)最为常见。炎症性关节炎占4.8%,自身免疫性皮肤病占18.4%。很少进行血清学筛查;18.4%的无已知甲状腺疾病的患者接受了促甲状腺激素治疗,6.5%的患者异常。维生素B12筛查异常的占8.9%,异常的占10.5%。恶性贫血抗体阳性率0.35%,均为阴性。结论:这项单中心队列研究表明,LS女性自身免疫性疾病的患病率很高,尤其是甲状腺疾病,为考虑促甲状腺激素筛查提供了支持。在该队列中,自身免疫性疾病的血清学检测很少被记录,而且关于恶性贫血的有限数据不足以评估建议的建议。研究结果还强调了自身免疫性关节炎和其他皮肤病的高负担,建议在这些领域进行临床评估。需要前瞻性多中心研究来告知和完善筛查建议。
{"title":"Autoimmune Disease Prevalence in Females With Vulval Lichen Sclerosus and Screening Patterns in a Multidisciplinary Vulval Unit.","authors":"Monica Narula, Emma Veysey","doi":"10.1111/ajd.70056","DOIUrl":"https://doi.org/10.1111/ajd.70056","url":null,"abstract":"<p><strong>Background/objectives: </strong>Vulval lichen sclerosus (LS) is a chronic inflammatory dermatosis with recognised associations with autoimmune disease, including thyroid disease, vitiligo, and psoriasis. Current expert consensus guidelines recommend investigating for autoimmune disease when clinically indicated by symptoms or signs. More recently, focused screening for thyroid disease and pernicious anaemia in women with LS has been proposed. This study aimed to assess the prevalence of autoimmune disease in a tertiary multidisciplinary vulval clinic and to determine whether findings from this cohort provide support for these proposed screening recommendations.</p><p><strong>Methods: </strong>A retrospective review of electronic medical records was conducted for patients attending a tertiary women's hospital vulval dermatology service between August 2020 and June 2025 with a diagnosis of LS. Data extracted included autoimmune history, serological testing for autoimmune disease (including thyroid function and pernicious anaemia), and family history. Descriptive statistics were used for analysis.</p><p><strong>Results: </strong>Eight hundred fifty-one patients met inclusion criteria. Autoimmune disease was recorded in 31.7%, with autoimmune thyroid disease (12.5%), lichen planus (8.23%), and psoriasis (5.05%) being most common. Inflammatory arthritis was present in 4.8% and autoimmune dermatological conditions in 18.4%. Serological screening was performed infrequently; thyroid stimulating hormone was performed in 18.4% of patients without known thyroid disease and 6.5% of these were abnormal. Vitamin B12 screening was performed in 8.9% and 10.5% were abnormal. Pernicious anaemia antibodies were performed in 0.35% and all were negative.</p><p><strong>Conclusions: </strong>This single-centre cohort study demonstrated a high prevalence of autoimmune disease in women with LS, particularly thyroid disease, providing support for consideration of thyroid stimulating hormone screening. Serological testing for autoimmune disease was infrequently documented in this cohort, and the limited data on pernicious anaemia were insufficient to evaluate the proposed recommendation. The findings also highlight a high burden of autoimmune arthritis and other dermatological conditions, suggesting a role for clinical assessment in these domains. Prospective multicentre studies are required to inform and refine screening recommendations.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients. 外阴硬化地衣与免疫检查点抑制剂治疗相关:11例病例系列。
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-02-02 DOI: 10.1111/ajd.70058
Sophie Walter, Francesca Watts, Raquel Ruiz Araujo, Thevaki Wain, Amanda Glanz, Diona Damian, Matteo S Carlino, Alexander M Menzies, Georgina V Long, Linda K Martin

There have only been a limited number of case reports that have described vulval lichen sclerosus in patients receiving immune checkpoint inhibitor (ICI) therapy. We describe 11 cases of vulval lichen sclerosus in patients with melanoma treated with ICIs, and in nine of these cases, the lichen sclerosus symptoms began after ICI commencement. This represents the largest reported series to date and highlights the need for clinician awareness of this potential immune-related adverse effect.

只有有限数量的病例报告描述了接受免疫检查点抑制剂(ICI)治疗的患者的外阴地衣硬化。我们描述了11例使用ICI治疗的黑色素瘤患者的外阴硬化地衣,其中9例在ICI开始后开始出现硬化地衣症状。这是迄今为止最大的系列报道,并强调临床医生需要认识到这种潜在的免疫相关不良反应。
{"title":"Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients.","authors":"Sophie Walter, Francesca Watts, Raquel Ruiz Araujo, Thevaki Wain, Amanda Glanz, Diona Damian, Matteo S Carlino, Alexander M Menzies, Georgina V Long, Linda K Martin","doi":"10.1111/ajd.70058","DOIUrl":"https://doi.org/10.1111/ajd.70058","url":null,"abstract":"<p><p>There have only been a limited number of case reports that have described vulval lichen sclerosus in patients receiving immune checkpoint inhibitor (ICI) therapy. We describe 11 cases of vulval lichen sclerosus in patients with melanoma treated with ICIs, and in nine of these cases, the lichen sclerosus symptoms began after ICI commencement. This represents the largest reported series to date and highlights the need for clinician awareness of this potential immune-related adverse effect.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of A PCR Based Microarray Assay for the Diagnosis of Superficial Fungal Infections. 基于PCR的微阵列检测对浅表真菌感染诊断的评价。
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-02-02 DOI: 10.1111/ajd.70057
Elena Khoo, Kenneth Fong, Benson Yeo, Pan Jiun Yit
{"title":"Evaluation of A PCR Based Microarray Assay for the Diagnosis of Superficial Fungal Infections.","authors":"Elena Khoo, Kenneth Fong, Benson Yeo, Pan Jiun Yit","doi":"10.1111/ajd.70057","DOIUrl":"https://doi.org/10.1111/ajd.70057","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rates of Self-Reported Skin Cancer in Current and Retired Elite Australian Cricketers. 澳大利亚现役和退役优秀板球运动员自我报告的皮肤癌发病率。
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-01-29 DOI: 10.1111/ajd.70055
John W Orchard, Georgia Redmayne, Brad Stenner, Alex J Chamberlain, Andrew Ming, Philippa Inge, Leona Yip

Background: Skin cancer rates are high in Australians, outdoor workers and physically active people. Australia is currently preparing a roadmap to better assess high risk groups for consideration of more targeted skin screening.

Methods: The membership of the Australian Cricketers Association (ACA), both current and retired cricketers, was invited to participate in a questionnaire survey to assess self-reported rates of skin cancer (and associated risk factors).

Results: Response rate was 451 subjects (29% of 1530 invited participants), of which 39% were female. Cohort self-reported melanoma rates were 1% for < 30 year olds, 8% for 51-60 year olds and 20% for those over 70 years old. BCC (basal cell carcinoma) rates for < 30 year olds were 1%, 33% for 51-60 year olds and 55% for those over 70 years old. SCC (squamous cell carcinoma) rates for < 30 year olds were 0%, 23% for 51-60 year olds and 38% for those over 70 years old. Very fair- or fair-skinned players (compared to medium- or dark-skinned players) and those who lived in lower latitudes (sunnier regions) as an adult experienced higher rates of all skin cancers. Females were less likely to have reported BCCs compared to males. The most common body area for skin cancer in cricketers (slightly over half of all cases) was the head/face/neck region.

Conclusion: The rates of BCC, SCC and melanoma in cricketers were high for almost all age groups. This is likely to represent a combination of true increase (due to a combination of sporting and leisure-time exposure) and bias due to methodological limitations. Fair-skinned cricketers can reasonably be considered a high-risk population in Australia who should exercise lifetime vigilance.

背景:澳大利亚人、户外工作者和体力活动者的皮肤癌发病率很高。澳大利亚目前正在制定路线图,以更好地评估高风险群体,以便考虑更有针对性的皮肤筛查。方法:澳大利亚板球运动员协会(ACA)的成员,包括现役和退役板球运动员,被邀请参加一项问卷调查,以评估自我报告的皮肤癌发病率(及相关危险因素)。结果:应答率为451人(占1530名受邀参与者的29%),其中女性占39%。结论:板球运动员的BCC、SCC和黑色素瘤的发病率几乎在所有年龄组中都很高。这可能是真实增加(由于运动和休闲时间暴露的结合)和由于方法限制而产生的偏差的结合。在澳大利亚,皮肤白皙的板球运动员可以被合理地视为高危人群,他们应该终生保持警惕。
{"title":"Rates of Self-Reported Skin Cancer in Current and Retired Elite Australian Cricketers.","authors":"John W Orchard, Georgia Redmayne, Brad Stenner, Alex J Chamberlain, Andrew Ming, Philippa Inge, Leona Yip","doi":"10.1111/ajd.70055","DOIUrl":"https://doi.org/10.1111/ajd.70055","url":null,"abstract":"<p><strong>Background: </strong>Skin cancer rates are high in Australians, outdoor workers and physically active people. Australia is currently preparing a roadmap to better assess high risk groups for consideration of more targeted skin screening.</p><p><strong>Methods: </strong>The membership of the Australian Cricketers Association (ACA), both current and retired cricketers, was invited to participate in a questionnaire survey to assess self-reported rates of skin cancer (and associated risk factors).</p><p><strong>Results: </strong>Response rate was 451 subjects (29% of 1530 invited participants), of which 39% were female. Cohort self-reported melanoma rates were 1% for < 30 year olds, 8% for 51-60 year olds and 20% for those over 70 years old. BCC (basal cell carcinoma) rates for < 30 year olds were 1%, 33% for 51-60 year olds and 55% for those over 70 years old. SCC (squamous cell carcinoma) rates for < 30 year olds were 0%, 23% for 51-60 year olds and 38% for those over 70 years old. Very fair- or fair-skinned players (compared to medium- or dark-skinned players) and those who lived in lower latitudes (sunnier regions) as an adult experienced higher rates of all skin cancers. Females were less likely to have reported BCCs compared to males. The most common body area for skin cancer in cricketers (slightly over half of all cases) was the head/face/neck region.</p><p><strong>Conclusion: </strong>The rates of BCC, SCC and melanoma in cricketers were high for almost all age groups. This is likely to represent a combination of true increase (due to a combination of sporting and leisure-time exposure) and bias due to methodological limitations. Fair-skinned cricketers can reasonably be considered a high-risk population in Australia who should exercise lifetime vigilance.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infectious Disease Screening and Vaccinations Guidelines for Patients Initiating Immunosuppression for Dermatologic Conditions: A Multidisciplinary Design and Quality Improvement Initiative. 皮肤病患者启动免疫抑制的传染病筛查和疫苗接种指南:多学科设计和质量改进倡议。
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-01-28 DOI: 10.1111/ajd.70046
Ruby S Gibson, Diana S Kim, Min Ji Her, Monica V Mahoney, Paula Stering, Simi Padival, Daniel Taupin, Martina L Porter

Through a multidisciplinary quality improvement initiative, the Pre-Immunosuppression (Pre-IS) Clinic was created at a tertiary referral institution to ensure appropriate vaccination and infectious disease screening for patients on immunosuppressive medications. Consensus guidelines on immunisation and infectious disease screening for immunosuppressed patients were created through a multidisciplinary committee. The guidelines included three sections: (1) screening recommendations for chronic/latent infections prior to immunosuppression, (2) immunisation recommendations for immunosuppressed patients and (3) recommendations for household contacts of immunosuppressed patients. The workflow to the Pre-IS Clinic was optimised. We present the vaccination guidelines and workflow as an effective example of a multidisciplinary qualitive improvement initiative.

通过一项多学科质量改进倡议,在一家三级转诊机构设立了免疫抑制前诊所,以确保对服用免疫抑制药物的患者进行适当的疫苗接种和传染病筛查。通过一个多学科委员会制定了免疫抑制患者免疫接种和传染病筛查的共识准则。指南包括三个部分:(1)免疫抑制前慢性/潜伏感染筛查建议,(2)免疫抑制患者免疫接种建议,(3)免疫抑制患者家庭接触者建议。Pre-IS诊所的工作流程得到了优化。我们提出疫苗接种指南和工作流程作为多学科质量改进倡议的有效例子。
{"title":"Infectious Disease Screening and Vaccinations Guidelines for Patients Initiating Immunosuppression for Dermatologic Conditions: A Multidisciplinary Design and Quality Improvement Initiative.","authors":"Ruby S Gibson, Diana S Kim, Min Ji Her, Monica V Mahoney, Paula Stering, Simi Padival, Daniel Taupin, Martina L Porter","doi":"10.1111/ajd.70046","DOIUrl":"https://doi.org/10.1111/ajd.70046","url":null,"abstract":"<p><p>Through a multidisciplinary quality improvement initiative, the Pre-Immunosuppression (Pre-IS) Clinic was created at a tertiary referral institution to ensure appropriate vaccination and infectious disease screening for patients on immunosuppressive medications. Consensus guidelines on immunisation and infectious disease screening for immunosuppressed patients were created through a multidisciplinary committee. The guidelines included three sections: (1) screening recommendations for chronic/latent infections prior to immunosuppression, (2) immunisation recommendations for immunosuppressed patients and (3) recommendations for household contacts of immunosuppressed patients. The workflow to the Pre-IS Clinic was optimised. We present the vaccination guidelines and workflow as an effective example of a multidisciplinary qualitive improvement initiative.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Pyoderma Gangrenosum Associated With Hidradenitis Suppurativa With Bimekizumab. 比美单抗成功治疗坏疽性脓皮病伴化脓性汗腺炎
IF 1.8 4区 医学 Q2 DERMATOLOGY Pub Date : 2026-01-28 DOI: 10.1111/ajd.70052
Martha A Oberg, Morgan Vague, Richard Zhang, Sharon I Choe, Alex G Ortega-Loayza
{"title":"Successful Treatment of Pyoderma Gangrenosum Associated With Hidradenitis Suppurativa With Bimekizumab.","authors":"Martha A Oberg, Morgan Vague, Richard Zhang, Sharon I Choe, Alex G Ortega-Loayza","doi":"10.1111/ajd.70052","DOIUrl":"https://doi.org/10.1111/ajd.70052","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Australasian Journal of Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1